Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
DiaMedica Therapeutics Inc. - Common Stock
(NQ:
DMAC
)
6.520
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 24, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about DiaMedica Therapeutics Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
Next >
DiaMedica (DMAC) Q2 2026 Earnings Call Transcript
↗
August 17, 2026
ReMEDy2 stroke trial nears interim analysis with 85% enrollment complete.
Via
The Motley Fool
Topics
Earnings
DiaMedica Therapeutics Q2 Earnings Call Highlights
↗
August 11, 2026
DiaMedica Therapeutics (NASDAQ:DMAC) said its second-quarter progress centered on advancing DM199 across early-onset fetal growth restriction (FGR), preeclampsia and acute ischemic stroke, while the...
Via
MarketBeat
Topics
Earnings
DiaMedica Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Highlights
August 10, 2026
From
DiaMedica Therapeutics Inc.
Via
Business Wire
DiaMedica Therapeutics (NASDAQ:DMAC) Posts Wider Q1 Loss but Clinical Catalysts Fuel Stock Resilience
↗
May 06, 2026
Via
Chartmill
Earnings Scheduled For November 12, 2025
↗
November 12, 2025
Via
Benzinga
DiaMedica Therapeutics to Report Second Quarter 2026 Financial Results and Provide a Business Update August 11, 2026
August 04, 2026
From
DiaMedica Therapeutics Inc.
Via
Business Wire
DiaMedica Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 17, 2026
From
DiaMedica Therapeutics Inc.
Via
Business Wire
DiaMedica Therapeutics Announces First Patients Dosed in Phase 2 Trial of DM199 for the Treatment of Fetal Growth Restriction
June 23, 2026
From
DiaMedica Therapeutics Inc.
Via
Business Wire
DiaMedica Receives FDA Feedback on DM199 Preeclampsia Nonclinical Program
June 16, 2026
From
DiaMedica Therapeutics Inc.
Via
Business Wire
DiaMedica (DMAC) Q4 2025 Earnings Transcript
↗
June 01, 2026
DiaMedica (DMAC) Q4 2025 Earnings Transcript
Via
The Motley Fool
Topics
Intellectual Property
DiaMedica Therapeutics to Present at the Jefferies Global Healthcare Conference 2026
May 27, 2026
From
DiaMedica Therapeutics Inc.
Via
Business Wire
DiaMedica Therapeutics Announces 75% Enrollment Milestone in ReMEDy2 Phase 2/3 Acute Ischemic Stroke Trial
May 20, 2026
From
DiaMedica Therapeutics Inc.
Via
Business Wire
DiaMedica Therapeutics to Participate in the 2026 RBC Capital Markets Global Healthcare Conference
May 12, 2026
From
DiaMedica Therapeutics Inc.
Via
Business Wire
DiaMedica (DMAC) Q1 2026 Earnings Transcript
↗
May 08, 2026
DiaMedica (DMAC) Q1 2026 Earnings Transcript
Via
The Motley Fool
Topics
Death
DiaMedica Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Highlights
May 06, 2026
From
DiaMedica Therapeutics Inc.
Via
Business Wire
DiaMedica Therapeutics to Report First Quarter 2026 Financial Results and Provide a Business Update May 7, 2026
April 30, 2026
From
DiaMedica Therapeutics Inc.
Via
Business Wire
RedChip's Biotech Virtual Investor Conference Replays Now Available
April 21, 2026
Via
ACCESS Newswire
RedChip's April 16 Virtual Investor Conference to Feature Companies Advancing Clinical Pipelines and Scalable Healthcare Platforms
April 07, 2026
Via
ACCESS Newswire
DiaMedica Therapeutics Reports Full Year 2025 Financial Results and Provides Business Highlights
March 30, 2026
From
DiaMedica Therapeutics Inc.
Via
Business Wire
Top Wall Street Forecasters Revamp DiaMedica Therapeutics Expectations Ahead Of Q4 Earnings
↗
March 30, 2026
DiaMedica Therapeutics (NASDAQ: DMAC) will release Q4 earnings on March 30. Analysts expect a quarterly loss of 18 cents per share. Stock fell 0.9% on Friday.
Via
Benzinga
DiaMedica Therapeutics to Report Fourth Quarter 2025 Financial Results and Provide a Business Update March 31, 2026
March 23, 2026
From
DiaMedica Therapeutics Inc.
Via
Business Wire
DiaMedica Therapeutics Receives Health Canada Clearance to Initiate Phase 2 Study of DM199 in Preeclampsia
March 05, 2026
From
DiaMedica Therapeutics Inc
Via
Business Wire
DiaMedica Therapeutics to Participate in Upcoming March Investor Conferences
February 24, 2026
From
DiaMedica Therapeutics Inc.
Via
Business Wire
DiaMedica Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 16, 2026
From
DiaMedica Therapeutics Inc.
Via
Business Wire
DiaMedica Therapeutics Provides DM199 Preeclampsia Program Update Following Pre-IND Meeting with FDA
December 18, 2025
From
DiaMedica Therapeutics Inc.
Via
Business Wire
12 Health Care Stocks Moving In Friday's After-Market Session
↗
November 14, 2025
Via
Benzinga
DiaMedica Therapeutics Inc (NASDAQ:DMAC) Reports Q3 2025 Earnings and Clinical Progress
↗
November 12, 2025
DiaMedica reports Q3 2025 results, advancing DM199 for stroke and preeclampsia. The company has a cash runway into H2 2027 to fund clinical trials.
Via
Chartmill
DiaMedica Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Highlights
November 12, 2025
From
DiaMedica Therapeutics Inc.
Via
Business Wire
An Overview of DiaMedica Therapeutics's Earnings
↗
November 11, 2025
Via
Benzinga
DiaMedica Therapeutics to Participate in the Jefferies Global Healthcare Conference in London
November 10, 2025
From
DiaMedica Therapeutics Inc.
Via
Business Wire
< Previous
1
2
3
4
5
6
7
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
